BCM
MRNA icon

Bluefin Capital Management’s Moderna MRNA Stock Holding History

Bluefin Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,508
Closed -$245K – 122
2020
Q2 		$225K Buy
+3,508
New +$192K 0.02% 220

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bluefin Capital Management's MRNA Position: Q3 2020 in Review

Bluefin Capital Management sold out of Moderna (MRNA) in Q3 2020, closing a stake of 3,508 shares — an estimated $245K sold.

Bluefin Capital Management first reported a position in MRNA in Q2 2020 and held it in 1 quarter. The position peaked at $225K in Q2 2020. 547 funds tracked by Wall St. Rank hold MRNA as of Q3 2020.

  • Bluefin Capital Management reported no remaining Moderna position as of Q3 2020 after selling out during the quarter.
  • Bluefin Capital Management sold 3,508 Moderna shares in Q3 2020, an estimated $245K.
  • Bluefin Capital Management first reported a position in Moderna in Q2 2020 and held it in 1 quarter.
  • Bluefin Capital Management's Moderna position peaked at $225K in Q2 2020.
  • 547 funds tracked by Wall St. Rank held Moderna as of Q3 2020.

Based on Bluefin Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.